Clinical

Stage

Item

Recommendations

Total Number

In Situ

Dermatology visits

Q 6 mo x 3 y, Q 12 mo x 2 y

8

IA = T1a

CMP, LDH

Each visit

6

CXR

optional, to address symptoms

0

Oncology visits

Q 6 mo x 1 y , Q12mo x 4 y

6

Dermatology visits

Q 4 mo x 1 y, Q 6 mo x 2 y, Q 12 mo x 2 y

9

IB = T1b

and T2a

CMP LDH

Each visit

9

CXR

X6

6

Oncology visits

Q 4 mo x 1 y, Q 6 mo x 2 y, Q 12 mo x 2 y

9

Dermatology visits

Q 3 mo x 1 y, Q 4 mo x 1 y, Q 6 mo x 2 y, Q 12 mo x 1 y

12

IIA = T2b

and T3a

CMP, LDH

Each one visit

11

CXR

x7

7

Oncology visits

Q 4 mo x 2 y, Q 6 mo x 1 y, Q 12 mo x 2 y

10

Dermatology visits

Q 3 mo x 1 y, Q 4 mo x 1 y, Q 6 mo x 2 y, Q 12 mo x 1 y

12

IIB = T3b

and T4a

CMP, LDH, CBC

Each visit

11

CXR

x7

7

Oncology visits

Q 4 mo x 2 y, Q 6 mo x 1 y, Q 12 mo x 2 y

10

Dermatology visits

Q 3 mo x 1 y, Q 4mo x 1 y, Q 6 mo x 3 y

13

IIC = T4b

CMP, LDH, CBC

Each one visit

11

CXR

x7

7

Oncology visits

Q 3 mo x 1 y, Q 4 mo x 1 y, Q 6 mo x 1 y, Q 12 mo x 2 y

11

Dermatology visits

Q 3 mo x 1 y, Q 4mo x 1 y, Q 6 mo x 3 y

13

IIIA

CMP, LDH, CBC

Each visit

11

CXR

x7

7

50% CT C/A/P

Q 12 mo x 5 y

5

PET

x1

2

Oncology visits

Q 3 mo x 1 y, Q 4 mo x 1 y, Q 6 mo x 1 y, Q 12 mo x 2 y

11

Dermatology visits

Q 3 mo x 1 y, Q 4 mo x 2y, Q 6 mo x 2 y

14

IIIB

CMP, LDH, CBC

Each visit

16

CXR

8

50% CT C/A/P

Q 6 mo x 1 y, Q 12 mo x 4 y

6

PET

x1

2

Oncology visits

Q 3 mo x 2 y, Q 4 mo x 2 y, Q 6 mo x 1 y

16

Dermatology visits

Q 3 mo x 1 y, Q 4 mo x 2y, Q 6 mo x 2 y

14

IIIC

CMP, LDH, CBC

Each visit

16

CXR

8

50% CT C/A/P

Q 6 mo x 1 y, Q 12 mo x 4 y

6

PET

x1

2

Oncology visits

Q 3 mo x 2 y, Q 4 mo x 2 y, Q 6 mo x 1 y

16

Dermatology visits

Q 3 mo x 1 y, Q 4 mo x 2y, Q 6 mo x 2 y

14

IV

Active treatment,

no surveillance